【病毒外文文獻(xiàn)】1994 Universal coronavirus vaccine_ spike protein cloning and expression for use as a recombinant vaccine

This section provides information on worldwide patents relevant to vaccine design and production The Patent Report gives the following information title of patent patentee patent number publication date and summary of the patent A number of patents m this report are reproduced from Blotechnology Abstracts with permission of Derwent Pubhcatlons Ltd Derwent House 14 Great Queen Street London WC2B 5DF UK Telephone 071 344 2800 Fax 071 344 2900 New dengue virus Type I strain recombinant DENI protein expression potential in recombinant vaccme constructmn virus detection and dengue fever diagnosis and therapy Umv Nat Smgapore World 9322 440 11 November 1993 Dengue wrus type 1 strata DEN 1 275 90 ECACC V92042111 is claimed Also claimed are 1 DEN1 S275 90 in reactivated form n a DNA molecule specified encoding DEN1 S275 90 m a fragment of a DNA molecule as m n the fragment encoding the C C PreM M E NS1 NS2A NS2B NS3 NS4A NS4B or NS5 gene of DEN1 S275 90 iv a DNA molecule or fragment as in u or nl m an expressmn vector v a cell harbourmg the expressmn vector vl a polypeptlde in isolated form which is the C C PreM M E NS1 NS2A NS2B NS3 NS4A NS4B or NS5 polypeptlde of DEN1 S275 90 vn an antibody against polypeptlde as m vl capable of binding a DEN1 viral porteln optmnally carrying a label and vm a kit for the detectmn of DEN1 virus DEN1 wrus was Isolated from the serum of a dengue haemorrhaglc fever patient RNA was isolated from the virus and used to prepare cDNA encoding DEN1 polypeptldes The Dengue virus type 1 can be used for detection diagnosis vaccines or treatment of DEN 1 infections 039 94 Non infective structural particle preparation containing flavlvlrus surface antigen protein Japanese encephalitis virus cDNA gene cloning in dengue vlrus 2 premfected cell with a vaccinia virus vector and use of a non infective structural parOcle as recombinant vaccine Ntppon Zeon Tokyoto Shmket Chem Jpn 05276 941 26 October 1993 In a new method a flavwlrus lnfected cell is infected with a recombinant vaccmm virus with integrated eDNA and non infective structural particles containing flawwrus E protein are separated The cDNA encodes substantmlly all of the flavlvlrus derived prM protein and surface antigen protein The mmal flavlvlrus is preferably dengue virus 2 and the eDNA encodes a Japanese encephalitis virus protein The sedimentation co efficient of the structural particle is below 100S The particle preparation may be used as a recombinant vaccine In an example Vero cells were infected prehmlnardy with dengue wrus 2 at an m o of 2 24 h prior to vacclma virus lnfectmn To 4 million premfected Vero cells recombinant vaccmla viruses LAJ6 Se and LAJ6 were infected at an m o t of 2 followed by culture for 18 h The supernatant was filtered 0 2 pm pore size and ultracentrlfuged at 150 0009 for 2 h The preopltate was washed with phosphate buffered saline suspended m 100 pl 10 mM carbonate buffer pH 9 8 diluted and coated 040 94 Universal coronavlrus vaccine spike protein cloning and expres sion for use as a recombinant vaccine SK Beecham World 9323 421 25 November 1993 A new polypeptlde contains a universal conserved domain 124 Potent Report amino acids from a coronavlrus or an lmmunogenlc fragment or derlvatwe and has less than a complete protein sequence of the spike S protein A recombinant vaccine containing the polypeptlde DNA encoding the polypeptlde and a method for protecting an animal against coronav rus refection using the vaccine are also new An identical 124 amino acid segment is found in the C terminal portion of S proteins of transmlsslble gastroententlS varus dog coronavlrus or cat coronavlrus stratus The sequence is highly conserved among eoronavlruses and is capable of ehcltmg a protectwe immune response against e g cat mfecuous perltonltIS virus cat enterlc coronavlrus dog coronav rus p g transm sslble gastroentent s virus cattle corona virus human coronawrus or bird Infectmus bronchms virus 041 94 Isolated specific epitope region of thyroid peroxldase for use as a recombinant vaccine in thyroid tumour or Hashlmoto disease immunotherapy Umv Mlchlgan World 9323 073 25 November 1993 A new method for screening for the presence of an autoantlbody to a thyrmd peroxidase EC1 11 1 7 in a sample for diagnosis of auto mmune thyroldms involves contact of a bmloglcal fluid e g serum or tissue sample with a pept de epitope with a defined protein sequence The peptlde may also be used as an lmmunostlmulant or vaccine for therapy or prevention of Hashlmoto disease or a thyroid tumour The peptlde is obtained from recombinant synthetic or native thyroid penoxadase DNA or RNA encoding the peptlde is also new The peptldes have distinct epltoplc regmns from amino acids 517 630 or 655 933 or thyroid peroxldase and may be used in lmmuno therapy By screening for antibodies against the peptldes patients with Hashlmoto disease may be distinguished from patients with other thyroid disorders e g Grave disease Thyroid peroxldase is a membrane antigen and is thus a good target for lmmunotherapy 042 94 Antltumour vaccine containing major histocompatibility complex protein for metastase control apphcaUon in cancer therapy Yeda Res Develop Eur 569 678 18 November 1993 An antltumour vaccine comprises a at least one type oftumour cell having two genes encoding and expressing in the cell major hlstocompatlbdity complex MHC proteins I of different haplotypes inserted into them where at least one I has the same haplotype as the individual being vaccinated and option ally 2 a pharmaceutically acceptable career and or diluent Preferably the cells are human tumour cells with or without metastatic potential The genes may encode MHC class I HLA A B or C protein or MHC class II HLA DR DQ or DP proteins The genes are inserted using a single or separate vectors for constitutive protein expression tn vtvo The vectors are plasmlds or retrowrus vectors and the genes either enter the cell chromosomes or are retained ep somally The tumour cells are inactivated after incorporation of the genes The vaccines can be used to treat tumours especially recurrent primary tumours and to prevent their subsequent formation Tumour cells carrying two MHC genes induce a protective mmune response which is a function of T lymphocyte reactivity and shows good long term memory 043 94 0264 410X 94 07 0671 01 1994 Butterworth Hememann Ltd Vaccine 1994 Volume 12 Number 7 671